Please login to the form below
Biogen
This page shows the latest Biogen news and features for those working in and with pharma, biotech and healthcare.
Biogen and Happify Health team up to create digital platform for MS patients
Biogen and Happify Health have revealed plans for a new collaboration to support people living with multiple sclerosis (MS), with the companies aiming to provide a digital solution for patient education ... As a global leader in developing treatments for
Latest news
-
EIT Health and Biogen announce winners of first ‘neurotechprize’
The winners of the first ‘neurotechprize’ have been announced by EIT Health, part of the European Institute of Innovation and Technology (EIT), a branch of the European Union, and Biogen. ... those affected, to make the diagnosis of AD easier,”
-
Biogen and Eisai announce FDA submission for early Alzheimer’s treatment
Biogen and Eisai have announced the rolling submission to the US Food and Drug Administration (FDA) for a Biologics License Application (BLA) for lecanemab.
-
Biogen and MedRhythms sign deal worth over $120m for digital therapeutics for MS patients
a common issue that impacts their overall quality of life,” said Martin Dubuc, head of Biogen Digital Health. ... According to the terms of the deal, Biogen is set to make an upfront payment of $3m to MedRhythms.
-
Biogen retracts EMA application for Alzheimer's drug Aduhelm
Following regulatory blocks and rejections late last year, Biogen has decided to withdraw its application for its Alzheimer's drug Aduhelm (aducanumab) in Europe. ... Biogen’s marketing authorisation had been re-evaluated by the CHMP in response to the
-
Biogen shares peer-reviewed publication of Aduhelm phase 3 data
Biogen has announced that a peer-reviewed manuscript has been published in The Journal of Prevention of Alzheimer’s Disease on data from the pivotal phase 3 EMERGE and ENGAGE trials ... The US Food and Drug Administration (FDA) granted Biogen
More from news
Approximately 172 fully matching, plus 327 partially matching documents found.
Latest Intelligence
-
After years of potential, cell and gene therapy is ready for the pharmaceutical mainstream
Another example is Biogen’s $800m acquisition of Nightstar’s late-stage gene therapy assets for retinal disease – NSR-REP1 and NSR-RPGR.
-
Switzerland: a life sciences hub
The country is thus home to AbbVie, Allergan, Amgen, AstraZeneca, Bayer, Biogen, Boehringer Ingelheim, Eli Lilly, Gilead, GlaxoSmithKline, Janssen, Lundbeck, MSD (Merck Sharp &Dohme), Pfizer, Sanofi and Takeda among others.
-
Alzheimer’s: the search for a cure
The whiplash turnaround is the result of Biogen’s analysis of data from two phase 3 trials. ... Baird analyst Brian Skorney is among the people who have a dim view of Biogen’s prospects.
-
20 for 2020 – Five pharma leaders to watch in 2020
Analysts think the deal could catapult Galapagos into the top tier of biopharma companies, joining the likes of Regeneron, Biogen and Roche’s Genentech unit, providing its pipeline delivers as hoped
-
Great expectations: the urgent need for common purpose in Alzheimer’s disease
Biogen surprised the world last autumn by announcing a re-evaluation of its latest aducanumab trial and the company is now expected to apply for regulatory approval.
More from intelligence
Approximately 2 fully matching, plus 45 partially matching documents found.
Latest appointments
-
BMS appoints new commercial leader, Davies joins Eisai and more
operations. She joins Sobi from Biogen, where she served as vice president for global supply chain operations and strategic partnerships.
-
Biogen appoints executive VP, corporate development
Biogen has appointed Daniel Karp as its executive vice president, corporate development effective 11 June. ... He said: “It's a privilege to join Biogen, a true leader in neuroscience," Karp said.
-
Gamida Cell strengthens leadership team
Nee will lead market research, analytics, forecasting, commercial strategies and competitive intelligence at the company, activities he has practised during his time with Biogen, Amgen and Novartis.
-
Editas Medicine names James Mullen as chairman
Before joining Patheon, Mullen served as chief executive officer and president at Biogen and before this he held numerous roles at the biotech.
-
Acumen appoints new strategy director
Thomas Bols will focus on reinforcing Acumen’s healthcare practice
More from appointments
Approximately 16 fully matching, plus 32 partially matching documents found.
Latest from PMHub
-
Viseven opens a new center of excellence in India
Biogen. Viseven enables an innovative governance model where a senior specialist is always involved in content production.
-
Mednet Group
Alzheimer’s Research UK. Alzheimer’s Society. Basic Needs. Biogen. Butterfly Scheme. Cardiomyopathy UK.
-
EPG Health
Strategic planning - to ensure ongoing engagement and success. Alexion, Almirall, Alnylam, AstraZeneca, Bial, Biogen, Bluebird Bio, Boehringer Ingelheim, BMS, CSL Behring, Ferring, Four Health, GSK, HRA Pharma, Janssen, Leo Pharma, Lilly,
-
Article: Market access in Brazil
In April 2019, Brazilian Health Minister Luiz Henrique Mandetta announced a pilot agreement for access to Biogen’s Spinal Muscular Atrophy (SMA) treatment Spinraza (nusinersen) through the Sistema Único de Saúde
-
IGNIFI
Allergan. Biogen. Boehringer Ingelheim. CO.DON. Danone Nutricia. Ferring Pharmaceuticals. GW Pharmaceuticals.
More from PMHub
Approximately 1 fully matching, plus 11 partially matching documents found.
Subscribe to our email news alerts
Featured jobs
- Senior Analyst, Market Access, UK, Home based
-
Highly competitive salary
- Medical Writer, MRNA/ Covid 19, Medical Communications, UK
-
Highly competitive salary
- Scientific Strategy Lead, Medical Communications, UK
-
Highly competitive salary
- Vice President, Medical Communications, UK, six figure package
-
Six figure salary
- Bristol Myers Squibb announces positive trial results for treatment of MS
- My journey advancing the science in pulmonary hypertension
- Enanta takes legal action against Pfizer over Paxlovid patent infringement
- FDA issues innovative proposal to increase nonprescription drug access
- Innovative Health Initiative launches first two calls for proposals to tackle ‘biggest’ health research challenges
- NHS App to revolutionise digital health and care with major digital updates by 2023
- NICE issues final draft recommending Novartis’ Scemblix to treat chronic myeloid leukaemia
- Alzheimer's Research UK supports government plans for clinical research
- GSK announces The HealthTree Foundation’s multiple myeloma programme as first ‘Think Tank’ challenge winner
- NRG Therapeutics partners with Domainex to develop neurodegenerative disease treatment
- Innovative Trials opens first US office
- Scanning for Health Indicators and Risks Through Your Smartphone
- College of Medicine launches Beyond Pills campaign to tackle overprescribing in UK health system
- AI is transforming pharma R&D – now it can transform pharma marketing
- Armoured CAR ‘could overwhelm solid tumour resistance’
- Six UK universities receive grant for research into motor neurone disease
- Realising the potential of omnichannel in medical communications
- Improving childhood cancer survival rates in developing countries
PMHub
Merrill Brink International
Merrill Brink International is a leading provider of life sciences, legal, financial, manufacturing and corporate language solutions for global companies....
Latest intelligence
- Our Top 5 Pharma Picks From Cannes Lions
- Here are five of Art's top five pharma and healthcare picks from Cannes Lions 2022....
- The Evolving Role of the Sales Rep
- The COVID-19 pandemic sparked an evolution in physician engagement. Jill Padgett, EdD, Head of Training, explores what this means for the sales force and shares her advice for succeeding in...
- Measure your omnichannel maturity with our new tool
- Try our Omnichannel Maturity Tool to gain tangible advice and an instant analysis of your omnichannel readiness....
